Professor Jason Trubiano

National Allergy Centre of Excellence Drug Allergy Stream Co-chair

ResearchGate | ORDCiD ID

  • Director of Infectious Diseases, Austin Health
  • Head for the Centre for Antibiotic Allergy and Research, Austin Health
  • NHMRC Emerging Leadership Fellow and Clinical Associate Professor, Department of Infectious Diseases, The University of Melbourne

Professor Jason Trubiano is an Infectious Diseases Physician and Director of Infectious Diseases. He is an NHMRC Emerging Leadership Fellow at Department of Infectious Diseases, The University of Melbourne and Cross Cutting Discipline Clinical Research Co-Lead at the Doherty Institute. He is the head for the Centre for Antibiotic Allergy and Research at Austin Health. The collaborative health services and translational research program focuses on drug hypersensitivity and antibiotic allergy. The Centre also hosts the National Antibiotic Allergy Network (NAAN) and Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR). NAAN is delivering a national Inpatient Penicillin Allergy Database, clinical and consumer protocols and antibiotic allergy advocacy and policy.

Prof Trubiano’s research explores health services programs for antibiotic allergy and novel diagnostics and pharmacogenomic predictors for severe T-cell mediated drug reactions. He leads clinical and translational studies at Austin Health and Peter MacCallum Cancer Centre investigating drug allergy and infections in the immunocompromised host. One of his current key projects is implementing point-of-care tools and precision medicine approaches for antibiotic allergy to improve prescribing and medication safety in health services.


Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy. JAMA Internal Medicine. Jul 2023

Development and Validation of a Sulfa Antibiotic Allergy Clinical Decision Rule. JAMA Network. Jun 2023

The Who, What, When and Where of Inpatient Direct Oral Penicillin Challenge - Implications for health services implementation. Clinical Infectious Diseases. Mar 2023

Safety of COVID ‐19 vaccine challenge in patients with immediate adverse reactions to prior doses: A multi‐centre cohort study. Allergy. Aug 2022

Use of a penicillin allergy clinical decision rule to enable direct oral penicillin provocation: an international multicentre randomised control trial in an adult population (PALACE): study protocol. BMJ Open. Aug 2022

Anaphylaxis in Victoria: presentations to emergency departments, with a focus on drug‐ and antimicrobial‐related cases. The Medical Journal of Australia. Mar 2022

Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study. Allergy. Nov 2021

Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context. Internal Medicine Journal. Sept 2021



Stay informed 

Sign up for NACE news and allergy study updates


Become a member 

Are you part of the Australian and New Zealand allergy research community?

Join us

Proudly in partnership with the National Allergy Council and allergy organisations